NCT05023265 Assessment of Quality of Life and Outcomes in Patients With Primary Renal Cell Carcinoma Treated With SBRT
| NCT ID | NCT05023265 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sunnybrook Health Sciences Centre |
| Condition | Renal Cell Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 70 participants |
| Start Date | 2022-02-08 |
| Primary Completion | 2026-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 70 participants in total. It began in 2022-02-08 with a primary completion date of 2026-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a multicenter, single arm phase II study of stereotactic body radiation therapy (SBRT) for patients with medically inoperable primary renal cell carcinoma (RCC).
Eligibility Criteria
Inclusion Criteria: * Patients ≥18 years old * Newly diagnosed RCC by biopsy (preferred) or radiologic evidence of growth on surveillance over two consecutive assessments (6-12 months) * Primary lesion \>3 cm, or recurrent lesion following local ablative therapy * Medically inoperable or patient who refuses surgery following assessment by experienced urologist, and discussed in a multidisciplinary setting * ECOG 0-2 * Written informed consent * Participants must be able to understand the English-language or with the aid of a translator Exclusion Criteria: * Primary Lesion \>20cm * Evidence of distant metastatic disease * Previous abdominal RT in vicinity of kidney preventing definitive SBRT * History of major radiosensitivity syndrome * Second invasive malignancy within the past 3 years (excluding non-melanomatous skin cancer) * Currently pregnant or lactating
Contact & Investigator
William Chu, MD, FRCPC
PRINCIPAL INVESTIGATOR
Sunnybrook Health Sciences Centre
Frequently Asked Questions
Who can join the NCT05023265 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Renal Cell Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05023265 currently recruiting?
Yes, NCT05023265 is actively recruiting participants. Contact the research team at chris.zehr@sunnybrook.ca for enrollment information.
Where is the NCT05023265 trial being conducted?
This trial is being conducted at Toronto, Canada.
Who is sponsoring the NCT05023265 clinical trial?
NCT05023265 is sponsored by Sunnybrook Health Sciences Centre. The principal investigator is William Chu, MD, FRCPC at Sunnybrook Health Sciences Centre. The trial plans to enroll 70 participants.